Bacille Calmette-Guérin revaccination is not efficacious for preventing sustained Mycobacterium tuberculosis infection.

A prior phase II trial had shown that BCG revaccination in teens led to 45.4% efficacy in reversion from positive to negative ...

Bacille Calmette-Guérin (BCG) revaccination is not efficacious for preventing sustained Mycobacterium tuberculosis infection, defined by sustained QuantiFERON-TB (QFT) test conversion ...

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

Our QuantiFERON tuberculosis test also delivered another strong quarter of double-digit sales growth as we continue to drive the transition to blood-based testing for TB testing from the outdated ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary ...

QIAGEN N.V.’s (QGEN - Free Report) first-quarter 2025 adjusted earnings per share (EPS) were 55 cents, and 56 cents at ...

The combined assessment of analysts suggests that 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' will likely reach $111.16 million. The estimate indicates a year-over-year change of ...

Diagnostic solutions registered the highest growth, driven by strong demand for QuantiFERON and QIAstat-Dx. PCR/Nucleic acid amplification technologies also posted solid growth, supported by the ...

Our growth pillars QIAstat-Dx and QuantiFERON both posted double-digit sales gains, while QIAcuity and QIAGEN Digital Insights both continued to build momentum and in Sample technologies we are ...